Mezzion Pharma Co.Ltd Market Cap ($289.01 Million)
Market Cap & Net Worth: Mezzion Pharma Co.Ltd (140410)
Mezzion Pharma Co.Ltd market cap. Mezzion Pharma Co.Ltd (KQ:140410) has a market capitalization of $289.01 Million (₩426.46 Billion) as of November 4, 2026. Listed on the KQ stock exchange, this Korea-based company holds position #14696 globally and #468 in its home market, demonstrating a -9.27% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Mezzion Pharma Co.Ltd's stock price ₩49900.00 by its total outstanding shares 8546310 (8.55 Million). Also see Mezzion Pharma Co.Ltd (140410) cash flow conversion for how efficiently the company converts equity into cash flow.
Mezzion Pharma Co.Ltd Market Cap History (2015–2026)
Mezzion Pharma Co.Ltd market cap history from 2015 to 2026. Data shows growth from $53.19 Million to $289.01 Million (16.75% CAGR). Check Mezzion Pharma Co.Ltd stock price for real-time trading data and today's change.
Index Memberships
Mezzion Pharma Co.Ltd is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Kosdaq Composite Index
KOSDAQ
|
$203.83 Billion | 0.14% | #144 of 1384 |
|
Kosdaq Composite Index
KQ11
|
$203.83 Billion | 0.14% | #144 of 1384 |
Weight: Mezzion Pharma Co.Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Mezzion Pharma Co.Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Mezzion Pharma Co.Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore net asset growth rate of Mezzion Pharma Co.Ltd to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.07x
Mezzion Pharma Co.Ltd's market cap is 0.07 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $44.40 Million | $8.75 Billion | -$12.98 Billion | 0.01x | N/A |
| 2017 | $77.03 Million | $5.59 Billion | -$14.88 Billion | 0.01x | N/A |
| 2018 | $177.61 Million | $19.09 Billion | -$18.88 Billion | 0.01x | N/A |
| 2019 | $369.32 Million | $18.93 Billion | -$23.25 Billion | 0.02x | N/A |
| 2020 | $339.39 Million | $28.63 Billion | -$13.83 Billion | 0.01x | N/A |
| 2021 | $419.13 Million | $26.65 Billion | -$13.60 Billion | 0.02x | N/A |
| 2022 | $75.29 Million | $30.73 Billion | -$36.30 Billion | 0.00x | N/A |
| 2023 | $225.88 Million | $31.72 Billion | -$12.73 Billion | 0.01x | N/A |
| 2024 | $178.67 Million | $8.61 Billion | -$19.48 Billion | 0.02x | N/A |
| 2025 | $521.83 Million | $7.91 Billion | -$34.93 Billion | 0.07x | N/A |
Competitor Companies of 140410 by Market Capitalization
Companies near Mezzion Pharma Co.Ltd in the global market cap rankings as of November 4, 2026. Also see total assets of Mezzion Pharma Co.Ltd for a full breakdown of the balance sheet.
Key companies related to Mezzion Pharma Co.Ltd by market ranking:
- Sam Chun Dang Pharm. Co. Ltd (KQ:000250): Ranked #5272 globally with a market cap of $2.49 Billion USD ( ₩3.67 Trillion KRW).
- ST Pharm Co.Ltd (KQ:237690): Ranked #8989 globally with a market cap of $902.70 Million USD ( ₩1.33 Trillion KRW).
- Aprogen Healthcare & Games Inc (KQ:109960): Ranked #16151 globally with a market cap of $209.26 Million USD ( ₩308.78 Billion KRW).
- NatureCell Co.Ltd (KQ:007390): Ranked #9557 globally with a market cap of $793.12 Million USD ( ₩1.17 Trillion KRW).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #5272 | Sam Chun Dang Pharm. Co. Ltd | KQ:000250 | $2.49 Billion | ₩171400.00 |
| #8989 | ST Pharm Co.Ltd | KQ:237690 | $902.70 Million | ₩71400.00 |
| #16151 | Aprogen Healthcare & Games Inc | KQ:109960 | $209.26 Million | ₩1728.00 |
| #9557 | NatureCell Co.Ltd | KQ:007390 | $793.12 Million | ₩22050.00 |
Market Capitalization of Mezzion Pharma Co.Ltd (2015–2026)
Market capitalization of Mezzion Pharma Co.Ltd from 2015 to today. Between 2015 and today, Mezzion Pharma Co.Ltd's market cap moved from $53.19 Million to $ 289.01 Million, with a yearly change of 16.75%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩289.01 Million | -44.62% |
| 2025 | ₩521.83 Million | +192.06% |
| 2024 | ₩178.67 Million | -20.90% |
| 2023 | ₩225.88 Million | +200.00% |
| 2022 | ₩75.29 Million | -82.04% |
| 2021 | ₩419.13 Million | +23.49% |
| 2020 | ₩339.39 Million | -8.10% |
| 2019 | ₩369.32 Million | +107.93% |
| 2018 | ₩177.61 Million | +130.58% |
| 2017 | ₩77.03 Million | +73.48% |
| 2016 | ₩44.40 Million | -16.52% |
| 2015 | ₩53.19 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Mezzion Pharma Co.Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $289.01 Million USD |
| MoneyControl | $289.01 Million USD |
| MarketWatch | $289.01 Million USD |
| marketcap.company | $289.01 Million USD |
| Reuters | $289.01 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Mezzion Pharma Co.Ltd
Mezzion Pharma Co.,Ltd. engages in the development, licensing, and commercialization of drugs for the treatment of vascular diseases. It is developing Udenafil, a PDE5 inhibitor to treat erectile dysfunction, benign prostatic hyperplasia, pulmonary arterial hypertension, overactive bladder, hepatic portal hypertension, and chronic obstructive pulmonary diseases. The company was formerly known as … Read more